

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

METROPOLITAN HEALTH NETWORKS INC
Form 10-Q
November 14, 2002

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2002

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number 0-28456

METROPOLITAN HEALTH NETWORKS, INC.
(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction of
Incorporation or organization)

65-0635748
(I.R.S. Employer
Identification No.)

500 Australian Avenue, West Palm Beach, Fl.
(Address of principal executive office)

33401
(Zip Code)

(561) 805-8500
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all Reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class -----	Outstanding as of September 30, 2002 -----
Common Stock par value \$.001	31,364,127

METROPOLITAN HEALTH NETWORKS, INC.

INDEX

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

	Page	

Part I.	FINANCIAL INFORMATION	
Item 1.	Condensed Consolidated Financial Statements (Unaudited):	
	Condensed Consolidated Balance Sheets as of September 30, 2002 and December 31, 2001	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2002 and 2001	4
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2002 and 2001	5
	Notes to Condensed Consolidated Financial Statements	6-12
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	
Item 4.	Controls and Procedures	
PART II.	OTHER INFORMATION	
	Summary of Legal Proceedings	19
	Changes in Securities and Use of Proceeds	19
	Default Upon Senior Securities	19
	Submission of Matters to a Vote of Security Holders	19
	Other Information	19
	Forward Looking Statements and Associated Risks	20
SIGNATURES		20

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

September 30, 20
(Unaudited)

ASSETS

CURRENT ASSETS

Cash and equivalents	\$ 219,066
Accounts receivable, net of allowances	14,305,882
Inventory	1,276,777
CDs-restricted	600,000
CDs receivable-restricted	400,000
Other current assets	499,855

Total current assets 17,301,580

PROPERTY AND EQUIPMENT, net 1,227,894

GOODWILL, net 1,993,824

OTHER ASSETS 350,001

TOTAL ASSETS \$ 20,873,299

=====

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable	\$ 4,110,919
Advances from HMO	663,953
Payroll taxes payable	3,387,185
Accrued expenses	876,838
Notes payable	1,387,205
Current maturities of capital lease obligations	123,958
Current maturities of long-term debt	578,751

Total current liabilities 11,128,809

CAPITAL LEASE OBLIGATIONS 134,705

LONG-TERM DEBT 2,769,089

CONTINGENCIES

STOCKHOLDERS' EQUITY

Preferred stock, par value \$.001 per share; stated value \$100 per share;
10,000,000 shares authorized; 5,000 issued and outstanding 500,000

Common stock, par value \$.001 per share; 80,000,000 shares authorized;
31,364,127 and 27,479,087 issued and outstanding 31,364

Additional paid-in capital 29,840,403

Accumulated deficit (23,188,126)

Common stock issued for services to be rendered (342,945)

Total stockholders' equity 6,840,696

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY \$ 20,873,299

=====

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

See accompanying notes - unaudited

3

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
 FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001

=====

	Nine Months Ended	
	SEPTEMBER 30, 2002 (Unaudited)	SEPTEMBER 30, 2001 (Unaudited)
REVENUES	\$ 114,723,677	\$ 92,357,885
EXPENSES		
Direct medical costs	93,090,296	78,619,733
Cost of sales	7,016,852	435,722
Payroll, payroll taxes and benefits	8,614,815	4,515,856
Medical supplies	1,414,464	55,236
Depreciation and amortization	797,529	612,122
Consulting expense	1,961,090	605,841
General and administrative	4,456,542	2,224,134
Total expenses	117,351,588	87,068,644
INCOME (LOSS) BEFORE OTHER INCOME (EXPENSE)	(2,627,911)	5,289,241
OTHER INCOME (EXPENSE):		
Interest and penalty expense	(1,664,498)	(492,063)
Other income	62,294	19,796
Total other income (expense)	(1,602,204)	(472,267)
INCOME (LOSS) FROM CONTINUING OPERATIONS	(4,230,115)	4,816,974
DISCONTINUED OPERATIONS:		
Loss from operations of discontinued operations	(481,901)	(405,787)
Loss on disposal of discontinued operations	(900,324)	--
LOSS FROM DISCONTINUED OPERATIONS	(1,382,225)	(405,787)
NET INCOME (LOSS) BEFORE INCOME TAXES	(5,612,340)	4,411,187
INCOME TAXES	--	63,827
NET INCOME (LOSS)	\$ (5,612,340)	\$ 4,347,360
Weighted Average Number of Common Shares Outstanding	30,068,891	\$ 25,333,662

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

Income (Loss) from continuing operations	=====	=====
	\$ (0.14)	\$ 0.19
Loss from discontinued operations	=====	=====
	\$ (0.05)	\$ (0.02)
Net earnings (loss) per share - basic	=====	=====
	\$ (0.19)	\$ 0.17
Net earnings (loss) per share - diluted	=====	=====
	\$ (0.19)	\$ 0.15
	=====	=====

See accompanying notes - unaudited

4

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001

=====

	SEPTEMBER 30, 2002 (Unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES:	
Net income (loss)	\$ (5,612,340)

Adjustments to reconcile net income (loss) to net cash used in operating activities:	
Provision for bad debt and additional IBNR	3,786,971
Loss on disposal of discontinued operations	900,324
Write-down of goodwill	22,209
Depreciation and amortization	1,087,299
Interest expense on beneficial conversion feature	808,372
Stock and warrants issued in lieu of cash for services	264,451
Changes in assets and liabilities:	
Accounts receivable, net	(4,730,071)
Inventory	(579,288)
Other current assets	(48,228)
Other assets	(640,469)
Accounts payable and accrued expenses	884,588
Payroll taxes payable	756,006
Due to related parties	--
Unearned revenue	--

Total adjustments	2,512,164

Net cash used in operating activities	(3,100,176)

CASH FLOWS FROM INVESTING ACTIVITIES:	
Purchase of restricted CDs	(600,000)

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

Capital expenditures	(263,481)

Net cash used in investing activities	(863,481)

CASH FLOWS FROM FINANCING ACTIVITIES:	
Net repayments on line of credit	--
Borrowings on notes payable	5,026,357
Repayments on notes payable	(1,063,014)
Net borrowings (repayments) on capital leases	(92,867)
Proceeds from issuance of stock	530,105
Proceeds from exercise of options	67
Cash paid for stock price guarantee on settlement of debt	(122,893)
Repayments on advances from HMO	(489,000)

Net cash provided by financing activities	3,788,755

NET INCREASE (DECREASE) IN CASH AND EQUIVALENTS	(174,902)
CASH AND EQUIVALENTS - BEGINNING	393,968

CASH AND EQUIVALENTS - ENDING	\$ 219,066
	=====

See accompanying notes - unaudited

5

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 (UNAUDITED)

NOTE 1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. Operating results for the three and nine months ended September 30, 2002 are not necessarily indicative of the results that may be expected for the year ending December 31, 2002.

The audited financial statements at December 31, 2001, which are included in the Company's Form 10-KSB, should be read in conjunction with these condensed consolidated financial statements.

SEGMENT REPORTING

The Company applies Financial Accounting Standards Boards ("FASB") statement No. 131, "Disclosure about Segments of an Enterprise and Related Information". The Company has considered its operations and has determined

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

that it operates in three operating segments for purposes of presenting financial information and evaluating performance, PSN (managed care and direct medical services), pharmacy and clinical laboratory. As such, the accompanying financial statements present information in a format that is consistent with the financial information used by management for internal use.

INCOME TAXES

The Company accounts for income taxes according to Statement of Financial Accounting Standards No. 109, which requires a liability approach to calculating deferred income taxes. Under this method, the Company records deferred taxes based on temporary differences between the tax bases of the Company's assets and liabilities and their financial reporting bases. A valuation allowance is established when it is more likely than not that some or all of the deferred tax assets will not be realized.

The effective tax rate for the nine months ended September 30, 2002 differed from the federal statutory rate due principally to an increase in the deferred tax asset valuation allowance.

REVENUES

Revenues are recorded when services are rendered or pharmacy products are sold. Revenues from one health maintenance organization (HMO) accounted for approximately 91% and 98% of the Company's total revenues for the quarters ended September 30, 2002 and 2001, and 90% and 98% for the nine months then ended.

Contracts with the HMO in the South Florida and Daytona markets renew automatically unless cancelled by either party with 120-day notice. These contracts expire December 31, 2002, however the contracts have been renewed for one year effective January 1, 2003. The Company expects the contracts to continue for the foreseeable future.

RECLASSIFICATION

Certain amounts reported in the comparative financial statements have been reclassified to conform with the presentation for the periods ended September 30, 2002.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

ACCOUNTS RECEIVABLE

Accounts receivable at September 30, 2002 and December 31, 2001 were as

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

follows:

	September 30, 2002	December 31, 2001
	-----	-----
HMO accounts receivable, net	\$11,037,000	\$10,540,000
Non HMO accounts receivable, net	3,269,000	2,823,000
	-----	-----
Accounts receivable	\$14,306,000	\$13,363,000
	=====	=====

In the health care environment, it is almost always at least reasonably possible that accounts receivable estimates could change in the near term as a result of one or more future confirming events. With regard to revenues, expenses and resulting accounts receivable arising from agreements with the HMO, the Company estimates amounts it believes will ultimately be realizable through the use of judgments and assumptions about future decisions. Programs with the HMO are sometimes complex and at times subject to different interpretation by the Company and the HMO. As a result certain revenue and cost estimates during the quarter may be settled for amounts different than previously estimated. To assist it in its efforts to estimate and ultimately collect amounts due from the HMO, the Company has contracted with several outside consultants that have worked closely with the HMO or other HMOs for extended periods of time. These consultants provide numerous services including, but not limited to, HMO revenue, expense and accounts receivable analysis and monthly claims and contestation analysis.

Direct HMO medical expenses are based in part upon estimates of claims incurred but not reported (IBNR) and estimates of retroactive adjustments to be applied by the HMO. The IBNR estimates are made by the HMO utilizing actuarial methods and are continually evaluated by management of the Company, based upon its specific claims experience. This evaluation is typically in conjunction with the Company's outside consultants. During the quarter ended June 30, 2002, as part of the Company's periodic review of medical claims, which are retroactively applied to the period in which they were incurred, management determined that the IBNR previously estimated were not sufficient to cover approximately \$2.0 million in retroactive claims that were charged to the Company. Accordingly, an adjustment to medical costs was recorded to cover the estimated IBNR shortfall. The estimates of retroactive adjustments to be applied by the HMO are based upon i) current agreements with the HMO to modify certain amounts previously charged to the Company and ii) Company estimates of certain charges the HMO has agreed were charged at incorrect rates but has not yet quantified.

The HMO has agreed to certain credits in their entirety and to analyze other amounts it has not yet quantified on certain past transactions. The HMO is in the process of quantifying past transactions charged at incorrect rates. In connection therewith, management has established a reserve of approximately \$1.5 million against the estimated net credits (aggregating \$8.6 million) and therefore \$7.1 million is included in accounts receivable, net of allowances. The estimated credits currently outstanding relate to the years from 2000 to the present. Management is in the process of, and intends to pursue collection of all estimated retroactive adjustments. Management believes its estimates of IBNR claims and estimates of retroactive adjustments are reasonable, however, it is reasonably possible the Company's estimate of these costs could change in the near term, and those changes may be material.

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

In addition to the retroactive adjustments, from time to time the Company is charged by the HMO for certain medical expenses which the Company believes it is not liable for. In connection therewith, the Company, through its outside consultants, is contesting certain costs aggregating approximately \$10.9 million. Management's estimate of recovery on these contestations is determined based upon its and the consultants' judgment, and their consideration of several factors including the nature of the contestations, historical recovery rates and other qualitative factors. Accordingly, accounts receivable due from the HMO includes approximately \$2.2 million, which represents estimated recovery of 20% of 2000, 2001 and 2002 contestations outstanding at September 30, 2002. It is reasonably possible the Company's estimate of these recoveries could change in the near term, and those changes may be material.

Under the contracts with the HMO, the Company receives payments from the HMO, net of direct medical costs paid on behalf of the Company, on a monthly basis. From time to time the HMO will also make advances to the Company. Payments on adjustments are paid as processed by the HMO. However, as it is sometimes difficult to quantify these adjustments, payment can often be delayed for extended periods.

7

Non-HMO accounts receivable, aggregating approximately \$7.7 million at September 30, 2002 relate principally to prescription sales and medical services provided on a fee for service basis, and are reduced by amounts estimated to be uncollectible (approximately \$4.4 million). Management's estimate of uncollectible amounts is based upon its analysis of historical collections and other qualitative factors, however it is reasonable possible the Company's estimate of uncollectible amounts could change in the near term, and those changes may be material. Non-HMO accounts receivable included approximately \$4.6 million from discontinued operations of which \$3.8 million is estimated to be uncollectible.

Non-HMO accounts receivable are typically uncollateralized customer obligations due under normal trade terms requiring payment within 30-90 days from the invoice date. The Company does not charge late fees or penalties on delinquent invoices, however it continually evaluates the need for a valuation allowance (Allowance). The Allowance reflects management's best estimate of the amounts that will not be collected. Management reviews all non-current accounts receivable balances on an ongoing basis and, based on this assessment of current creditworthiness, estimates the portion, if any, that will not be collected. It is reasonably possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

NET INCOME PER SHARE

The Company applies Statement of Financial Accounting Standards No. 128, "Earnings Per Share" (FAS 128) which requires dual presentation of net income per share; Basic and Diluted. Basic earnings per share is computed using the weighted average number of common shares outstanding during the period; 31,273,935 and 30,068,891 for the three and nine months ended September 30, 2002. Diluted earnings per share is computed using the weighted average number of common shares outstanding during the period adjusted for incremental shares attributed to outstanding options and

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

warrants to purchase shares of common stock. Outstanding stock equivalents were not considered in the calculation of diluted earnings (loss) per common share for the three and nine months ended September 30, 2002, as their effect would have been anti-dilutive.

	Nine Months Ended	
	9/30/02	9/30/01
Net Income (loss)	\$ (5,612,340)	\$ 4,347,360
Less: Preferred stock dividend	--	(37,500)
Income (loss) available to common shareholders	\$ (5,612,340)	\$ 4,309,860
Denominator:		
Weighted average common shares outstanding	30,068,891	25,333,662
Basic earnings (loss) per common share	\$ (0.19)	\$ 0.17
Net Income (loss)	\$ (5,612,340)	\$ 4,347,360
Interest on convertible securities	--	32,327
Weighted average common shares outstanding	30,068,891	28,590,688
Diluted earnings (loss) per common share	\$ (0.19)	\$ 0.15

NEW ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board ("FASB") issued three new pronouncements: Statement of Financial Accounting Standards ("SFAS") No 141, "Business Combinations," SFAS No. 142, "Goodwill and Other Intangible Assets" and SFAS No. 143, "Accounting for Asset Retirement Obligations." In August 2001, the FASB issued SFAS No. 144, "Accounting for the impairment or Disposal of Long-Lived Assets." SFAS No. 141 is effective as follows: a) use of the pooling-of-interest method is prohibited for business combinations initiated after June 30, 2001; and b) the provisions of SFAS 141 apply to all business combinations accounted for by the purchase method that are completed after June 30, 2001 (that is, the date of the acquisition is July 2001 or later). There are also transition provisions that apply to business combinations completed before July 1, 2001, that were accounted for by the purchase method. SFAS No. 142 is effective for fiscal years beginning after December 15, 2001 for all goodwill and other intangible assets recognized in

an entity's statement of financial position at that date, regardless of when those assets were initially recognized. SFAS No. 142 specifies that goodwill and some intangible assets will no longer be amortized but instead will be

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

subject to periodic impairment testing. The Company adopted certain provisions of these pronouncements effective July 1, 2001, as required for goodwill and intangible assets acquired in purchase business combinations consummated after June 30, 2001. The Company adopted the remaining provisions of SFAS 141 and SFAS 142 effective January 1, 2002. There was not a cumulative transition adjustment upon adoption as of July 1, 2001 or January 1, 2002. SFAS 141 and SFAS 142 required the Company to perform the following as of January 1, 2002; (i) review goodwill and intangible assets for possible reclassifications; (ii) reassess the lives of intangible assets; and (iii) perform a transitional goodwill impairment test. The Company has reviewed the balances of goodwill and identifiable intangibles and determined that the Company does not have any amounts that are required to be reclassified from goodwill to identifiable intangibles, or vice versa. The Company has also reviewed the useful lives of its identifiable intangible assets and determined that the original estimated lives remain appropriate. The Company has completed the transitional goodwill impairment test and has determined that the Company did not have a transitional impairment of goodwill.

As required by SFAS 142, the Company has not amortized goodwill associated with acquisitions completed after June 30, 2001, or any period presented and ceased amortization of goodwill associated with acquisitions completed prior to July 1, 2001, effective January 1, 2002. Prior to January 1, 2002, the Company amortized goodwill associated with the pre-July 1, 2001 acquisitions over ten years using the straight-line method. A reconciliation of reported net income (loss) adjusted to reflect the adoption of SFAS No. 142 is provided below:

	For the Nine Months Ended September 30,		
	2002	2001	
Reported net income (loss)	\$ (5,612,340)	\$ 4,347,360	\$
Add-back goodwill amortization, net of tax	--	294,367	
Adjusted net income (loss)	\$ (5,612,340)	\$ 4,641,727	\$
Reported basic net income per share	\$ (0.19)	\$ 0.17	\$
Add-back goodwill amortization	--	0.01	
Adjusted basic net income (loss) per share	\$ (0.19)	\$ 0.18	\$
Reported diluted net income (loss) per share	\$ (0.19)	\$ 0.15	\$
Add-back goodwill amortization	--	0.01	
Adjusted diluted net income (loss) per share	\$ (0.19)	\$ 0.16	\$

SFAS No. 143 requires entities to record the fair value of a liability for an asset retirement obligation in the period in which it is incurred and a corresponding increase in the carrying amount of the related long-lived asset. Subsequently, the asset retirement cost should be allocated to

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

expense using a systematic and rational method over its useful life. SFAS No. 143 is effective for fiscal years beginning after June 15, 2002. The Company is currently assessing the impact of SFAS No. 143, which is not expected to have a material impact on the Company's financial statements.

SFAS No. 144 addresses financial accounting and reporting for the impairment of long-lived assets and for long-lived assets to be disposed of. It supersedes, with exceptions, SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of" and is effective for fiscal years beginning after December 15, 2001. The Company has adopted SFAS No. 144, and it did not have a material impact on the Company's financial statements.

In April 2002, the FASB issued SFAS No. 145, rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13 and Technical Corrections. This statement, among other things, eliminated an inconsistency between required accounting for certain sale-leaseback transactions and provided for other technical corrections. Management believes adoption of this statement will not have a material effect on the financial statements of the company.

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities. This statement addresses accounting and reporting for costs associated with exit or disposal activities and nullifies emerging issues Task Force Issue No. 94-3. The statement is effective for exit or disposal costs initiated after December 31, 2002, with early application encouraged. This statement has not yet been adopted by the Company and management has not determined the impact of this statement on the financial statements of the Company.

9

NOTE 3. LIQUIDITY AND CAPITAL RESOURCES

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States, which contemplates continuation of the Company as a going concern. However, the Company has incurred negative cash flows from operations, partly as a result of the Company's diversification of its revenue base, including the pharmacy and clinical laboratory operations. Although the Company expects its cash flow from operations to continue to improve, there can be no assurance that this will occur. In the absence of achieving positive cash flows from operations or obtaining additional debt or equity financing, the Company may have difficulty meeting current and long-term obligations, and may be forced to discontinue a material business segment or overall operations.

In the first nine months of 2002, the Company issued 500,000 shares of common stock in connection with private placement offerings, resulting in net proceeds of \$500,000. Additionally, the Company borrowed \$1,700,000 in short-term notes payable and \$2,780,000 in long-term notes and debentures, with varying interest rates and maturities (see Notes 5-6).

Management has negotiated and is in the process of closing an accounts receivable financing agreement to support the growth in its pharmacy division. In addition, the Company projects cash flow from HMO agreements to increase in 2003 from the expansion and implementation of new agreements.

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

Also, management has taken measures to reduce overhead and is reviewing its operations for further reductions.

In conjunction with its review of its operations, the Company decided to dispose of its clinical laboratory, which the Company believes will result in an increase in both operational profitability and cash flow. Accordingly, in the quarter ended September 30, 2002, the Company recognized a \$1.2 million loss on disposal of discontinued operations.

In view of these matters, realization of a major portion of the assets in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to meet its financial obligations. Management believes that actions presently being taken, as described in the preceding paragraphs, provide the opportunity for the Company to continue as a going concern, however, there is no assurance this will occur.

NOTE 4. EQUITY LINE OF CREDIT AGREEMENT

On March 30, 2001, the Company entered into an equity line of credit agreement with a British Virgin Islands corporation (Purchaser), in order to establish a possible source of funding for the Company's planned operations. The equity line of credit agreement established what is sometimes also referred to as an equity draw down facility (Equity Facility). Under the Equity Facility, the Purchaser agreed to provide the Company with up to \$12,000,000 of funding during the twenty-four (24) month period following the date of an effective registration statement. During this twenty-four (24) month period, the Company may request a draw down under the Equity Facility by selling shares of its common stock to the Purchaser, and the Purchaser would be obligated to purchase the shares.

During 2002, the Company received approximately \$40,000 under the Equity Facility and on March 5, 2002, the Company terminated the Equity Facility.

NOTE 5. SHORT-TERM DEBT

In the first quarter of 2002, the Company borrowed a total of \$1,700,000 due in June 2002, since extended through February 2003. The notes bear interest of 24-25% and are collateralized by a total of 3,200,000 shares of common stock and by all the Company's assets. The proceeds from these transactions were used for working capital.

NOTE 6. LONG-TERM DEBT

In May 2002, the Company entered into a "Securities Purchase Agreement", in which it issued \$1,580,000 6% Convertible debentures due May 24, 2004 and 150,000 warrants to purchase common stock. The purchase price for the promissory note and Warrants was \$1,501,000 or 95% of the principal amount of the Convertible Debentures. The Holder shall have the right at its option to convert the Convertible Debenture into shares of common stock. The number of shares shall be determined by dividing the conversion amount (principal

plus accrued interest) by the conversion price as defined (\$0.43 per share

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

at issuance). In connection with the issuance of the convertible debentures the company recorded an interest charge of \$808,000 relating to the beneficial conversion feature. Approximately \$60,000 of the purchase price was assigned to the warrants and this amount, along with the \$79,000 discount, is being amortized and charged to interest expense over two years under the interest method.

Also in May 2002, the Company entered into a "Securities Purchase Agreement" in which the Company issued a \$1,200,000 principal amount Promissory Note due May 24, 2004 and 500,000 warrants to purchase common stock. The purchase price for the promissory note and warrants was \$1.2 million. Interest is payable quarterly at a rate of 12% per annum, commencing June 30, 2002, and principal is due at maturity. Approximately \$254,000 of the purchase price was assigned to the warrants and this amount is being amortized and charged to interest expense over two years under the interest method.

NOTE 7. STOCKHOLDERS' EQUITY

During the first quarter of 2002, the Company issued 500,000 shares of common stock to accredited investors, resulting in proceeds of \$500,000. In addition, the Company issued approximately 1,200,000 shares of common stock to convert approximately \$1,100,000 of long-term debt to equity.

NOTE 8. STOCK OPTIONS

The Company adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," ("SFAS 123") in 1997. The Company has elected to continue using Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" in accounting for employee stock options.

Accordingly, compensation expense has been recorded to the extent the market value of the underlying stock exceeded the exercise price at the date of grant. For the three and nine months ended September 30, 2002 no compensation was recorded. During those same periods in 2001, there was no compensation in the three months and approximately \$54,000 in the nine months ended September 30, 2001.

NOTE 9. COMMITMENTS AND CONTINGENCIES

LITIGATION

The Company is a party to various claims arising in the ordinary course of business. Management believes that the outcome of these matters will not have a material adverse effect on the financial position or the results of operations of the Company.

PAYROLL TAXES PAYABLE

In 2000, the Company negotiated an installment plan with the Internal Revenue Service (IRS) related to unpaid payroll tax liabilities including interest and penalties totaling approximately \$2.1 million at September 30, 2002. Under the plan the Company made monthly installments of \$100,000 on the amount in arrears. This agreement has expired and the full amount is deemed due upon demand. The Company is currently negotiating with the IRS for a new installment agreement and has proposed a three-year payout whereby the liability would be retired at the end of the agreement. This amount plus approximately \$1.3 million related to 2002 payroll taxes are included as

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

payroll taxes payable at September 30, 2002. While management believes it will be successful in negotiating a new agreement, there can be no assurance that the IRS will accept the proposal on these delinquent taxes.

LETTER OF CREDIT

In March 2002, two investors, on behalf of the Company, provided funding for certificates of deposit aggregating \$1,000,000 that are used as collateral for a letter of credit in favor of the HMO. The letter of credit was required by the Company's contract with the HMO and enabled the Company to favorably renegotiate certain terms of the contract. Included in CDs receivable - restricted are CDs (collateralizing the Letter of Credit) that the Company has purchased from investors. Payments for these CDs are due over ten months at amounts that result in an effective interest rate of 24% per annum and at September 30, 2002, \$600,000 had been purchased.

11

NOTE 10. BUSINESS SEGMENT INFORMATION

The Company has considered its operations and has determined that it operates in three operating segments for purposes of presenting financial information and evaluating performance, PSN (managed care and direct medical services), pharmacy and clinical laboratory. The Company has allocated corporate overhead to the clinical laboratory during the time the laboratory was operational. However, the overhead allocation is not included in the loss from operations of the discontinued business segment shown in the condensed consolidated statements of operations. The PSN segment also includes all costs incurred in the development of the Company's HMO.

THREE MONTHS ENDED SEPTEMBER 30, 2002	PSN	PHARMACY	LABO
Revenues from external customers	\$ 34,613,000	\$ 3,096,000	\$
Intersegment revenues	--	308,000	
Revenues from discontinued business segment	--	--	1
Segment gain (loss) before allocated overhead	1,488,000	(364,000)	(1,3
Allocated corporate overhead	1,231,000	569,000	
Segment gain (loss) after allocated overhead	257,000	(933,000)	(1,3
THREE MONTHS ENDED SEPTEMBER 30, 2001	PSN	PHARMACY	LABO
Revenues from external customers	\$ 32,000,000	\$ 322,000	
Intersegment revenues	--	164,000	
Revenues from discontinued business segment	--	--	1
Segment gain (loss) before allocated overhead	3,012,000	(263,000)	(1
Allocated corporate overhead	962,000	201,000	1
Segment gain (loss) after allocated overhead	2,050,000	(464,000)	(2

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

NINE MONTHS ENDED SEPTEMBER 30, 2002	PSN	PHARMACY	LABO
Revenues from external customers	\$ 105,226,000	\$ 9,498,000	
Intersegment revenues	--	870,000	
Revenues from discontinued business segment	--	--	1,0
Segment gain (loss) before allocated overhead	2,892,000	(1,050,000)	(1,3
Allocated corporate overhead	3,743,000	1,907,000	4
Segment gain (loss) after allocated overhead	(851,000)	(2,957,000)	(1,8
NINE MONTHS ENDED SEPTEMBER 30, 2001	PSN	PHARMACY	LABO
Revenues from external customers	\$ 92,012,000	\$ 346,000	
Intersegment revenues	--	164,000	
Revenues from discontinued business segment	--	--	19
Segment gain (loss) before allocated overhead	9,163,000	(283,000)	(40
Allocated corporate overhead	3,338,000	293,000	49
Segment gain (loss) after allocated overhead	5,825,000	(576,000)	(90

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Metropolitan Health Networks, Inc. (the "Company" or "Metcare ") was incorporated in the State of Florida in January 1996. In 2000, the Company implemented its new strategic plan, operating as a Provider Service Network

12

(PSN), specializing in managed care risk contracting. The Company's ability to control its Network has produced favorable medical loss ratios, allowing the Company to successfully tap into the trillion dollar healthcare market. Through its Network, the Company provides care to over 27,000 Medicare+Choice patients, 3,000 commercial HMO patients and approximately 15,000 fee-for-service patients aligned with various health plans.

The primary focus of the PSN division is the continuous development and expansion of its network and infrastructure to provide services under its existing HMO contract. Current legislation and a political environment that has demonstrated support for the Medicare+Choice program have augmented many opportunities in the managed care industry. An example of this support is the current additional funding that has been proposed to begin in 2003, along with bonuses for health plans that are willing to establish a presence in underserved markets. The Company's business plan is modeled to take full advantage of the new direction of the Medicare+Choice program with the initial underserved market of the Treasure Coast of Florida (Martin, St. Lucie and Okeechobee Counties) as

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

well as expanding its market share in South and Central Florida.

Responding to rapid increases in pharmacy spending, in June of 2001 the Company formed Metcare Rx, Inc., a wholly owned subsidiary, to control costs and to reduce prescription drug expenditures that are forecasted to increase by over 100% in the next decade. An increasing number of health plans with low-cost co-pays for drug coverage, direct-to-consumer advertising, and newer, better therapies requiring high-cost branded products all drive up the cost of pharmacy benefits. In an effort to reduce these costs, the Company has negotiated agreements allowing the Company to directly negotiate contracts for the purchase, filling and delivery of prescriptions. The Company believes it can achieve better management and control to provide cost savings and incremental revenues. As of the date of this filing, Metcare Rx operates in New York, Maryland and various locations in Florida, with additional contracts to provide services in Buffalo, New York beginning later in 2002 or early 2003.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in conformity with generally accepted accounting principles requires the Company's management to make a variety of estimates and assumptions. These estimates and assumptions affect, among other things, the reported amounts of assets and liabilities, the disclosure of contingent liabilities and the reported amounts of revenues and expenses. Actual results can differ from the amounts previously estimated, which were based on the information available at the time the estimates were made.

The critical accounting policies described below are those that the Company believes are important to the portrayal of the Company's financial condition and results, and which require management to make difficult, subjective and/or complex judgments. Critical accounting policies cover accounting matters that are inherently uncertain because the future resolution of such matters is unknown. The Company believes that critical accounting policies include accounts receivable and revenue recognition, use of estimates and goodwill.

Accounts Receivable and Revenue Recognition

The Company is a party to certain managed care contracts and provides medical care to its patients through owned and non-owned medical practices. In connection with its Provider Service Network (PSN) operations, the Company is exposed to losses to the extent of its share of deficits. Accordingly, revenues under these contracts are reported as PSN revenue, and the cost of provider services under these contracts are reported as an operating expense.

The Company recognizes non-PSN revenues, net of contractual allowances, as medical services are provided or pharmaceuticals are sold. These services or goods are typically billed to patients, Medicare, Medicaid, health maintenance organizations, insurance companies and other third parties. The Company provides an allowance for uncollectible amounts and for contractual adjustments relating to the difference between standard charges and agreed upon rates paid by certain third party payers.

Use of Estimates-PSN

In HMO-PSN arrangements, it is almost always at least reasonably possible that accounts receivable estimates could change in the near term as a result of one or more future confirming events. With regard to revenues, expenses and resulting accounts receivable arising from agreements with the HMO, the Company estimates amounts it believes will ultimately be realizable through the use of

judgments and assumptions about future decisions. Contractual terms with the HMO are sometimes complex and at times subject to different interpretation by the Company and the HMO. As a result certain revenue, expense and accounts receivable estimates may differ from amounts recorded in the financial statements and may require subsequent adjustments. To assist estimating and collecting amounts due from the HMO, the Company has contracted with several outside consultants that have worked closely with the HMO or other HMOs for extended periods of time. These consultants provide numerous services including, but not limited to, HMO revenue, expense and accounts receivable analysis and monthly claims and contestation analysis. However, it is still reasonably possible that actual results may differ from the estimates.

Direct HMO medical expenses include costs incurred directly by the Company and costs paid by the HMO on the Company's behalf. These costs also include estimates of claims incurred but not reported (IBNR), estimates of retroactive adjustments to be applied by the HMO and adjustments for charges which the Company believes it is not liable ("contestations"). The IBNR estimates are made by the HMO utilizing actuarial methods and are continually evaluated and adjusted by management of the Company, based upon its specific claims experience and input from outside consultants. The Company bases its estimates of retroactive adjustments on agreements with the HMO to modify previous charges. Some of these adjustments have been quantified while others involve situations where the HMO has agreed the charges were at incorrect rates, but they have not yet quantified the difference. Contestations involve charges where the Company, with the assistance of its consultants, contests certain expenses charged by the HMO. The estimate of direct medical expense includes an estimated recovery of 20% of outstanding contestations with the HMO. It is reasonably possible that estimates of such recoveries could change and the effect of the change could be material.

Accounts receivable from the HMO represents the combined effect of the Company's interpretation of the contract with the HMO and the HMO payment patterns. Collection times on these accounts typically exceed normal collection periods reflecting the need to reconcile the different interpretations and the HMO's cash management practices.

Goodwill

The Company has made several acquisitions in the past that included a significant amount of goodwill. Under generally accepted accounting principles in effect thorough December 31, 2001, these assets were amortized over their useful lives and tested periodically to determine if they were recoverable from operating earnings on a discounted basis over their useful lives.

Effective January 1, 2002, goodwill is accounted for under SFAS No. 142, "Goodwill and Other Intangible Assets". The new rules eliminate amortization of goodwill but subject these assets to impairment tests. See "New Accounting Pronouncements" in Note 2 for a more complete discussion. Management is required to make assumptions and estimates, such as the discount factor, in determining fair value. Such estimated fair values might produce significantly different results if other reasonable assumptions and estimates were to be used.

RESULTS OF OPERATIONS

The Company had revenues of \$37.7 million for the quarter ended September 30, 2002 and operating expenses of \$38.0 million, resulting in a loss from

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

operations of approximately \$310,000 and a net loss of approximately \$2.0 million, inclusive of the \$1.3 million loss on disposition of its clinical laboratory discussed below. For the nine months ended September 30, 2002, the Company had revenues of \$114.7 million and operating expenses of \$117.4 million, a loss from operations of approximately \$2.6 million and a net loss of approximately \$5.6 million. Included in the quarter and nine months ended September 30, 2002 are approximately \$1.3 million and \$1.4 million, respectively, in losses related to the disposal of the Company's clinical laboratory. Management believes that the disposal of the lab will result in both an increase in operational profitability and cash flow on a go-forward basis. In addition, included in the nine months ended September 30, 2002 are significant adjustments of approximately \$5.4 million, as discussed below. Excluding these adjustments and the disposal of the lab, the Company's operating expenses would have been \$112.8 million for the nine months ended September 30, 2002, resulting in income from operations of \$2.0 and net income of \$1.2 million. The net loss for the quarter ended September 30, 2002, exclusive of the loss on disposal of the lab, would have been \$676,000.

For the same periods in 2001, revenues amounted to \$32.3 million for the quarter and \$92.4 million for the nine months, resulting in net income of \$1.3 million and \$4.3 million respectively. On a diluted per share basis, earnings were \$0.04 and \$0.15 for the quarter and nine months ended September 30, 2001, respectively, compared to losses of \$0.06 and \$0.19 for the same periods in 2002.

In addition, the Company had working capital of \$6.2 million at September 30, 2002 compared to \$8.8 million a year earlier while shareholders' equity was \$6.8 million at September 30, 2002 compared to \$11.8 million at September 30, 2001.

As disclosed in its previous SEC filings, the Company makes certain cost estimates with regards to its contract with the HMO. Programs with the HMO are sometimes complex and at times subject to different interpretation. These cost estimates may be settled for amounts different than previously estimated or the

14

Company's estimate of these costs could change in amounts that could be material to the financial statements. As such, these estimates are continuously reviewed and, based on its second quarter review, management determined that an adjustment to direct medical costs of approximately \$2.0 million relating to prior IBNR estimates was required. In addition, management felt an additional reserve on the remaining carrying amounts of its estimated retroactive cost adjustments would be prudent. Although it will aggressively attempt to collect these amounts, the Company established a \$1.5 million reserve by a charge to its direct medical costs in the second quarter.

Additionally, direct medical expenses are based in part upon estimates of claims incurred but not reported (IBNR) by the HMO utilizing actuarial methods, and are continually evaluated by management of the Company based upon its specific claims experience. During the second quarter the HMO revised its Part A (hospital) IBNR methodology, resulting in a charge to direct medical costs of \$1.1 million.

In conjunction with a Convertible Debenture financing completed in May 2002, the Company incurred a second quarter charge to interest of approximately \$808,000. This charge was necessary as the holder may convert the debt at any time into company stock at a price lower than it was at the issuance of the debt.

During 2001, in an effort to diversify its revenue base and ultimately increase

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

shareholder value, the Company implemented its pharmacy division and began the process of filing for its own HMO license. As such, the results for the quarter and nine months ended September 30, 2002 included losses incurred by the Company's pharmacy and HMO divisions, as well as its clinical laboratory, which, including allocation of corporate overhead, totaled approximately \$953,000 for the quarter and \$3.6 million for the nine months. It is expected that these operations, in total, will achieve profitability in the fourth quarter of 2002 through a combination of increased revenue and cost cutting measures. In line with this goal, the Company decided to dispose of its clinical laboratory, which should result in both an increase in operational profitability and cash flow. Accordingly, in the quarter ended September 30, 2002, the Company recognized \$1.3 million in losses on discontinued operations.

Quarter Ended September 30, 2002

REVENUES

Revenues for the quarter ended September 30, 2002 increased 17% compared to the same period in 2001, from \$32.3 million to \$37.7 million. PSN revenues from the HMO increased \$2.4 million from \$31.8 million to \$34.2 million. September 2002 PSN revenues included approximately \$1.5 million of additional Medicare and commercial funding over the September 2001 quarter and the Company expects to receive similar additional monthly amounts for the foreseeable future. An increase in the number of covered lives within the PSN network accounted for the balance of the increase in revenues over the prior year.

Revenues for the third quarter of 2002 included approximately \$3.4 million from Metcare Rx, the Company's pharmacy division, which began operations in the Daytona market in June 2001, New York in July 2001, and Maryland in October 2001. For the same period in 2001, pharmacy revenues were only \$486,000. Management believes that with the proper capitalization, MetcareRx will eventually account for a significant percentage of overall revenues of the Company as it continues to expand in its existing markets and enter other markets. Pharmacy sales to the PSN of approximately \$308,000 have been eliminated in consolidation. In addition, revenues for the third quarter of 2002 included \$602,000 from its Daytona oncology offices, as compared to nothing the prior year. These increases were offset, in part, by approximately \$200,000 in decreases due to a closed medical practice and a reduction in fee-for-service revenue in its primary care medical offices.

EXPENSES

Operating expenses for the third quarter of 2002 were \$38.0 million, a 24% increase over prior year operating expenses of \$30.7 million. Direct medical costs for the quarter ended September 30, 2002 were \$29.9 million compared to \$27.3 million for the quarter ended September 30, 2001. Direct medical costs, the largest component of expense, represent certain costs associated with providing services of the PSN operation including direct medical payments to physician providers, hospitals and ancillaries on a capitated or fee for service basis. As a percentage of PSN revenues, the medical loss ratio (MLR) amounted to 87.4% and 85.7% for the quarters ended September 30, 2002 and 2001, respectively. This increase due primarily due to increases in Part A (hospital) costs due to new contracts with hospitals in the Company's Daytona network. These increases were offset in part by the Company's continually improving utilization initiatives, including its hospitalist, partners in quality (PIQ), and oncology programs.

Cost of sales for the third quarter of 2002 totaled \$2.4 million and represents the cost of the pharmaceuticals sold by MetcareRx. The pharmacy division had a gross profit percentage for the 2002 quarter of 31%.

Salaries and benefits for the third quarter of 2002 increased \$994,000 over the third quarter of the prior year to \$2.8 million. MetcareRx, the Company's pharmacy division, accounted for \$697,000 of the increase, while expansion of the services the Company provides in its Daytona market in an effort to control its medical costs accounted for \$317,000 of increases. The Company believes it has the necessary management in place to support the revenue growth the Company anticipates in 2003 and beyond.

Medical supplies were \$644,000 for the September quarter, compared to \$27,000 in 2001. Medical supply costs are incurred in all the Company's medical offices, most prominently in the Company's two Daytona oncology offices, which accounted for \$630,000 of the quarter's expense.

Depreciation and amortization for the quarter ended September 30, 2002 was \$265,000 compared to \$202,000 the year before. The increase is due primarily to depreciation on fixed assets acquired over the past twelve months.

Consulting expense increased approximately \$282,000, from \$316,000 in the quarter ended September 30, 2001 to \$598,000 in the same period in 2002. Of the increase, \$248,000 was incurred in the Company's Hospitalist, Oncology and Utilization/Quality Assurance/Management programs, which are designed to lower direct medical costs while improving patient care, and \$20,000 was spent in the development of the Company's HMO, part of its long-term goal to diversify its revenue base.

General and administrative expenses increased from \$719,000 in the third quarter of 2001 to \$1.5 million in the third quarter of 2002, an increase of \$781,000. The pharmacy operations accounted for \$340,000 in incremental general and administrative expenses while the costs of the Company's oncology and hospitalist programs and other PSN expansion accounted for an additional \$166,000 in incremental costs. The prior year quarter also included approximately \$112,000 in accounts payable write-offs and settlements relating to discontinued operations and \$98,000 in incremental insurance increases.

Interest expense increased \$255,000 for the September quarter due to the increased amount of debt carried by the Company at September 30, 2002 as compared to the prior year.

Nine Months Ended September 30, 2002

REVENUES

Revenues for the nine months ended September 30, 2002 increased 24% compared to the same period in 2001, from \$92.4 million to \$114.7 million. PSN revenues from the HMO increased \$13.0 million from \$91.0 million to \$104.0 million. September 2002 PSN revenues included approximately \$4.7 million of additional Medicare and commercial funding over the nine months ended September 2001 and the Company expects to receive similar additional monthly amounts for the foreseeable future. In addition, an increase in the number of covered lives within the PSN network contributed approximately \$8.3 million of the increase in revenues over the prior year.

Revenues for the first nine months of 2002 included approximately \$10.4 million from Metcare Rx, the Company's pharmacy division, which began operations in the Daytona market in June 2001, New York in July 2001, and Maryland in October 2001. For the same period in 2001, pharmacy revenues were only \$511,000. Management believes that with the proper capitalization, MetcareRx will

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

eventually account for a significant percentage of overall revenues of the Company as it continues to expand in its existing markets and enter other markets. Pharmacy sales to the PSN of approximately \$870,000 have been eliminated in consolidation. In addition, revenues for 2002 included \$1.3 from its Daytona oncology offices, as compared to nothing the prior year. These increases were partially offset by decreases in revenue due to closed medical practices totaling \$354,000 over 2001.

EXPENSES

Operating expenses for first nine months of 2002 increased 35% over the prior year, higher than the 24% increase in revenues. However, included in 2002 are approximately \$4.6 million in significant charges to direct medical costs, as discussed above. Exclusive of these charges, operating expenses increased 29%, more in line with its increase in revenues.

Direct medical costs for the nine months ended September 30, 2002 were \$93.1 million compared to \$78.6 million for the same period in 2001. Exclusive of the charges discussed above, the expense for 2002 would have been \$88.5 million,

16

more in line with the increase in PSN revenue. Direct medical costs, the largest component of expense, represent certain costs associated with providing services of the PSN operation including direct medical payments to physician providers, hospitals and ancillaries on a capitated or fee for service basis. As a percentage of PSN revenues, the medical loss ratio (MLR) amounted to 89.5% and 86.4% for the nine months ended September 30, 2002 and 2001, respectively. Adjusted for the charges discussed above, the MLR for the 2002 would amount to 85.0%, a 1.4% improvement over 2001. This improvement resulted from the Company's continually improving utilization initiatives, including its hospitalist, partners in quality (PIQ), and oncology programs, and the increased funding it received during 2002, offset in part by increases in Part A (hospital) costs due to new contracts with hospitals in the Company's Daytona network.

Cost of sales for the first three quarters of 2002 totaled \$7.0 million and represents the cost of the pharmaceuticals sold by MetcareRx. The pharmacy division had a gross profit percentage for the six months ending September 30, 2002 of 32%.

Salaries and benefits for the first nine months of 2002 increased \$4.1 million over 2001 to \$8.6 million. Since June 30, 2001, the Company expanded its operations as it continued to implement its business plan. In July 2001, a medical center was opened in Boca Raton, incurring \$241,000 in incremental payroll costs for the first nine months of 2002, with other PSN medical offices opened in March 2001 accounting for an additional \$201,000 in increases. MetcareRx accounted for \$2.6 million of incremental payroll costs in its Florida, New York and Maryland facilities. Expansion of the services the Company provides in its Daytona market in an effort to control its medical costs accounted for an additional \$974,000 of the increase while salary increases, increases in medical insurance premiums and a bolstering of staffing throughout the Company, particularly in the PSN, accounted for the balance of the increase, which was partially offset by a \$91,000 incremental decrease resulting from the closure of a medical practice in the second half of 2001. The Company believes it has the necessary management in place to support the revenue growth the Company anticipates in 2002 and beyond.

Medical supplies were \$1.4 million for the nine months ended September 30, 2002,

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

compared to \$55,000 in 2001. Medical supply costs are incurred in all the Company's medical offices, most prominently in the Company's two Daytona oncology offices, which account for all but \$54,000 of the quarter's expense.

Depreciation and amortization for the nine months ended September 30, 2002 was \$798,000 compared to \$612,000 the year before. The increase of approximately \$186,000 is due primarily to amortization of financing costs and an increase in depreciation on fixed assets acquired over the past twelve months.

Consulting expense increased approximately \$1.4 million, from \$606,000 in the nine months ended September 30, 2001 to \$2.0 million in the same period in 2002. Of the increase, \$806,000 was incurred in the Company's Hospitalist, Oncology and Utilization/Quality Assurance/Management programs, which are designed to lower direct medical costs while improving patient care, \$358,000 of incremental expense was incurred in connection with investment banking and advisory services and \$162,000 was spent in the development of the Company's HMO, part of its long-term goal to diversify its revenue base.

General and administrative expenses increased from \$2.2 million in the first three quarters of 2001 to \$4.5 million in 2002, an increase of \$2.3 million. The pharmacy operations accounted for \$1.3 million in incremental general and administrative expenses while the costs of the Company's oncology and hospitalist programs and other PSN expansion accounted for an additional \$401,000 in incremental costs. Increases also were incurred in accounting and legal fees (\$156,000) and insurance (\$166,000). The prior year quarter also included approximately \$313,000 in accounts payable write-offs and settlements relating to discontinued operations, These increases were partially offset by the savings of \$142,000 resulting from the closure of a medical practice in the second half of 2001.

Interest expense increased \$1.2 million for the nine months ended September 30, 2002 as compared to 2001, due in large part to the previously mentioned charge to interest expense of \$808,000 incurred in conjunction with a Convertible Debenture financing completed in May 2002. The balance of the increase is due to the increased amount of debt carried by the Company at September 30, 2002 as compared to the prior year.

LIQUIDITY AND CAPITAL RESOURCES

During the nine months ended September 30, 2002 the Company raised approximately \$5.2 million in debt and equity financing. However, the Company has sustained negative cash flows from operations since 2000, primarily as a result of the Company's diversification of its revenue base, including the pharmacy and

17

clinical laboratory operations. Although the Company expects its cash flow from operations to continue to improve, there can be no assurance that this will occur. In the absence of achieving positive cash flows from operations or obtaining additional debt or equity financing, the Company may have difficulty meeting current and long-term obligations. The auditor's report on the Company's financial statements for the year ended December 31, 2001 states that certain matters raise substantial doubt about the Company's ability to continue as a going concern.

To address these concerns, the Company has negotiated and is in the process of closing an accounts receivable financing agreement to support the growth in its pharmacy division. In addition, the Company projects cash flow from HMO agreements to increase significantly in 2003 from expansion and implementation

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

of new agreements. Also, management has taken measures to reduce overhead and is reviewing its operations for further reductions.

In conjunction with its review of its operations, the Company decided to dispose of its clinical laboratory. Accordingly, in the quarter ended September 30, 2002, the Company recognized \$1.3 million in losses on discontinued operations. Management has implemented and continues to review other cost cutting measures as well as potential sources of increased revenue in order to accomplish its goals.

In view of these matters, realization of a major portion of the assets in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company's ability to meet its financial obligations. Management believes that actions presently being taken, as described in the preceding paragraphs, provide the opportunity for the Company to continue as a going concern.

During the first quarter of 2002, the Company issued 500,000 shares to accredited investors, in connection with private placements, resulting in proceeds of \$500,000 that were used for working capital. Additionally, the Company borrowed \$1.7 million on short-term notes payable that were due June 2002, since extended, and \$625,000 in long-term notes payable, with varying interest rates ranging from 5% to 24% and beneficial conversion features. Certain notes also provided for issuance of 65,000 warrants in the aggregate and are collateralized by all the Company's assets. The proceeds from these transactions were used for working capital. Such offerings were to accredited investors pursuant to Section 4(2) of the Securities and Exchange Act of 1934.

In May 2002, the Company entered into a "Securities Purchase Agreement", in which it issued \$1,580,000 6% Convertible debentures due 5/24/04 and 150,000 warrants to purchase common stock. The purchase price for the promissory note and Warrants was \$1,501,000 or 95% of the principal amount of the Convertible Debentures. The Holder shall have the right at its option to convert the Convertible Debenture into shares of common stock. In addition, in May the Company entered into a "Securities Purchase Agreement" in which the Company issued a \$1,200,000 principal amount Promissory Note due 5/24/04 and 500,000 warrants to purchase common stock. The purchase price for the promissory note and warrants was \$1.2 million. Interest is payable quarterly at a rate of 12% per annum, commencing June 30, 2002, and principal is due at maturity.

The primary source of the Company's liquidity is derived from payments from its full-risk contracts with an HMO. In March 2002, two investors, on behalf of the Company, funded \$1.0 million as collateral for a letter of credit in favor of the HMO. The letter of credit was required by the Company's contract with the HMO and enabled the Company to favorably renegotiate certain terms of the contract. The Company has agreed to purchase the collateral over ten months at an effective rate of 24% per annum and at September 30, 2002, \$600,000 had been purchased.

As discussed in Note 2, the Company, in conjunction with its outside consultants, makes certain estimates with regards to revenues, expenses and resulting accounts receivable arising from agreements with the HMO. While the Company believes these amounts will ultimately be realizable, the collection cycle of these estimated amounts usually exceeds the typical collection time required to collect medical accounts receivable. Often these amounts are subject to different interpretation by the Company and the HMO and, accordingly, needs to be reconciled with the HMO. As a result, certain revenue and cost estimates may be settled for amounts different than previously estimated. Accordingly, management recorded a reserve of \$1.5 million against these receivables in the second quarter.

At September 30, 2002 the Company had a recorded liability for unpaid payroll

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

taxes of approximately \$2.2 million, exclusive of accrued interest and penalties of \$1.2 million. The Company previously negotiated an installment plan with the Internal Revenue Service (IRS) whereby it made monthly installments of \$100,000 on the amount in arrears. The Company is currently negotiating with the IRS for a new installment agreement and has proposed a three-year payout whereby the liability would be retired at the end of the agreement.

18

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

None

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

Within the 90 days prior to the filing date of this report, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. This evaluation was done under the supervision and with the participation of the Company's Principal Executive Officer and Principal Financial Officer. Based upon that evaluation, they concluded that the Company's disclosure controls and procedures are effective in gathering, analyzing and disclosing information needed to satisfy the Company's disclosure obligations under the Exchange Act.

Changes in internal controls

There were no significant changes in the Company's internal controls or in other factors that could significantly affect those controls since the most recent evaluation of such controls.

PART II OTHER INFORMATION

ITEM 1. SUMMARY OF LEGAL PROCEEDINGS

None

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

NONE

ITEM 3. DEFAULT UPON SENIOR SECURITIES

NONE

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

NONE

ITEM 5. OTHER INFORMATION

NONE

Edgar Filing: METROPOLITAN HEALTH NETWORKS INC - Form 10-Q

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

EXHIBITS

- No. 99.1 - Certification of CEO
- No. 99.2 - Certification of CFO

19

FORWARD-LOOKING STATEMENTS AND ASSOCIATED RISKS

Except for historical information contained herein, the matters discussed in this report are forward-looking statements made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on the Company's expectation and are subject to a number of risks and uncertainties, including but not limited to economic, competitive and other factors affecting the Company's operations, ability of the Company to obtain competent medical personnel, the cost of services provided versus payment received for capitated and full-risk managed care contracts, negative effects of prospective healthcare reforms, the Company's ability to obtain medical malpractice coverage and the cost associated with malpractice, access to borrowed or equity capital on favorable terms, the fluctuation of the Company's common stock price, and other factors discussed elsewhere in this report and in other documents filed by the Company with the Securities and Exchange Commission from time to time. Many of these factors are beyond the Company's control. Actual results could differ materially from the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this report will, in fact, occur.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the Undersigned thereunto duly authorized.

METROPOLITAN HEALTH NETWORKS, INC.
Registrant

Date: November 14, 2002

/s/ Fred Sternberg

Fred Sternberg
Chairman, President and
Chief Executive Officer

Date: November 14, 2002

/s/ David S. Gartner

David S. Gartner
Chief Financial Officer

20

